{
  "pmcid": "4565859",
  "sha256": "f71e489d2da85fd876f1827925cddedb47476bf6e5b32640002756e25b0ec8ac",
  "timestamp_utc": "2025-11-09T22:42:54.078373+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 10.058172900061315,
    "reading_ease": 42.71238912732477,
    "word_count": 233
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of [99m Tc]Tilmanocept in Sentinel Lymph Node Biopsy for Head and Neck Squamous Cell Carcinoma"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "This multicenter, non-randomized, single-arm trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "enrolled 101 patients with T1–T4, N0, and M0 HNSCC across 13 centers. Eligibility required no prior neck dissection or radiotherapy."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Patients received 50 µg [99m Tc]tilmanocept radiolabeled with either 0.5 mCi (same day) or 2.0 mCi (next day)"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluated the false negative rate (FNR) of sentinel lymph node biopsy (SLNB) using [99m Tc]tilmanocept"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the FNR of SLNB, measured from June 2009 to November 2012."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "enrolled 101 patients with T1–T4, N0, and M0 HNSCC across 13 centers"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Of 85 patients injected, 83 underwent SLNB/END."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Among 39 patients with tumor-positive nodes, one had a false negative, yielding an FNR of 2.56% (95.03% CI 0.06–13.49; p = 0.0205)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No drug-related serious adverse events were reported."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT00911326."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 17,
    "max_score": 25
  }
}